Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

axitinib

- PMLiVE

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

- PMLiVE

New ABPI president pledges closer collaboration with NHS

UK pharma body appoints a president and vice president for the first time

- PMLiVE

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

A round-up from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

The latest news from across pharma, biotech and healthcare

- PMLiVE

Pharma demands guarantees for UK sector deal

Ten companies warn of Brexit threat, and long-standing flaws in medicines access

- PMLiVE

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

Highlights from the world of pharma, biotech and healthcare

- PMLiVE

NICE set to reject Kyowa Kirin’s Crysvita for XLH

Committee says the rare disease therapy isn’t value for money

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links